Trial Profile
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Sep 2015
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Irinotecan
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 19 Feb 2013 Actual end date Nov 2012 added as reported by ClinicalTrials.gov.
- 22 Oct 2012 Planned end date changed from 1 Nov 2012 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 19 Apr 2012 Planned end date changed from 1 Apr 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.